Gubra

finance numbers tape money
Biotech

AbbVie pays Gubra $350M to make late play for obesity space

The outlay, plus up to $1.875 billion in milestones, has landed AbbVie rights to a long-acting amylin analog that is in phase 1 development at Gubra.
Nick Paul Taylor Mar 3, 2025 4:48am
Two injectable medications with a tape measure wrapped around them

Gubra reveals early data for once-weekly obesity asset

Nov 13, 2024 5:56pm